Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda files NDA for diabetes drug
The new drug application (NDA) submission was supported by two Phase III clinical trials, involving more than 2,000 patients worldwide. The studies assessed the efficacy and safety of
The new drug application (NDA) submission was supported by two Phase III clinical trials, involving more than 2,000 patients worldwide. The studies assessed the efficacy and safety of
The trial will compare the dermal bioavailability and will measure the systemic exposure of lidocaine in one of the leading marketed products, Xylocaine (5% lidocaine), and Phosphagenics’s lidocaine
In clinical studies, ProAir HFA, the albuterol sulfate inhaler, exhibited significant bronchodilator efficacy in pediatric asthmatics aged four to 11 years. According to the company, ProAir HFA provides
Under terms of the agreement, Microbix has acquired the urokinase inventory, regulatory filings and related assets for an upfront payment of $2 million and the assumption of $500,000
Analysis of these five-year data demonstrates that the addition of Erbitux to radiation therapy resulted in a significant increase in median overall survival for patients with squamous cell
The FDA based its approval on the results of a multicenter, randomized, double-blind, placebo-controlled study demonstrating that Nasacort AQ can be used safely and effectively to treat nasal
The primary objective of the Improve study was to evaluate the efficacy of the new formulation of Rebif, compared to placebo, in patients with relapsing-remitting multiple sclerosis (RRMS)
The grant award is the first installment of the combined $2.5 million grant from the National Institutes of Health (NIH) to clinically evaluate the therapeutic feasibility of treating
While an analysis of the one-month preclinical safety studies is ongoing, the company has initiated a three-month preclinical safety program in order to support further clinical evaluation of
DentalMed has begun the registration process of ViziLite Plus in Russia and will begin training its sales representatives and preparing the market for the product launch after the